On October 29, 2025, Thermo Fisher Scientific announced it entered into a definitive agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash at closing. The transaction is expected to be completed by the middle of 2026 and is subject to customary closing conditions and regulatory approvals.

8-KOther EventsFiled Oct 29, 2025Period of report Oct 29, 2025Summary published (UTC) Oct 12, 2026

Key points

AI summary

On October 29, 2025, Thermo Fisher Scientific announced it entered into a definitive agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash at closing. The transaction is expected to be completed by the middle of 2026 and is subject to customary closing conditions and regulatory approvals.
In addition to the cash purchase price at closing, Thermo Fisher agreed to pay $125 million in deferred consideration and up to $400 million in contingent consideration following the closing. The company said it will pay $125 million in January 2027 and up to $400 million in earn-out payments based on Clario's business performance in 2026 and 2027.
Thermo Fisher said Clario is expected to generate approximately $1.25 billion of revenue for the full year 2025. The company said the acquisition will add $0.45 to adjusted earnings per share in the first year after close and is immediately accretive to adjusted operating margin.
Thermo Fisher said it intends to fund the transaction using proceeds from debt financing and cash on hand. Upon close, Clario will become part of Thermo Fisher's Laboratory Products and Biopharma Services segment.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Thermo Fisher Scientific Enters into Definitive Agreement to Acquire Clario Holdings

On October 29, 2025, Thermo Fisher Scientific announced it entered into a definitive agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash at closing. The transaction is expected to be completed by the middle of 2026 and is subject to customary closing conditions and regulatory approvals.

Source · Based on the filing body and exhibits

Deferred and Contingent Consideration

In addition to the cash purchase price at closing, Thermo Fisher agreed to pay $125 million in deferred consideration and up to $400 million in contingent consideration following the closing. The company said it will pay $125 million in January 2027 and up to $400 million in earn-out payments based on Clario's business performance in 2026 and 2027.

Source · Based on the filing body and exhibits

Clario Business Scale and Post-Acquisition Financial Outlook

Thermo Fisher said Clario is expected to generate approximately $1.25 billion of revenue for the full year 2025. The company said the acquisition will add $0.45 to adjusted earnings per share in the first year after close and is immediately accretive to adjusted operating margin.

Source · Based on the filing body and exhibits

Acquisition Financing and Segment Integration

Thermo Fisher said it intends to fund the transaction using proceeds from debt financing and cash on hand. Upon close, Clario will become part of Thermo Fisher's Laboratory Products and Biopharma Services segment.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.